Literature DB >> 22902296

MicroRNAs: novel mediators of resistance to microtubule-targeting agents.

Arun Kanakkanthara1, John H Miller.   

Abstract

MicroRNAs (miRNAs) are small, non-coding RNAs that act as expression regulators of genes involved in diverse cellular processes, including cell proliferation, differentiation, and apoptosis. Abnormal expression of miRNAs can have profound effects on cellular function, and miRNAs are implicated in tumourigenesis either as oncogenes or tumour suppressors. Deregulated miRNAs have been shown to have a role in the resistance of cancer cells to microtubule-targeting agents (MTAs). Here, we discuss how altered expression of miRNAs mediates resistance to clinically useful MTAs, such as paclitaxel and vincristine. Understanding the molecular role of miRNAs in drug resistance would help improve therapeutic efficacy of these agents by helping circumvent the problem of drug resistance.
Copyright © 2012 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22902296     DOI: 10.1016/j.ctrv.2012.07.005

Source DB:  PubMed          Journal:  Cancer Treat Rev        ISSN: 0305-7372            Impact factor:   12.111


  12 in total

1.  miR-195 potentiates the efficacy of microtubule-targeting agents in non-small cell lung cancer.

Authors:  Xiaojie Yu; Yiqiang Zhang; Xiuye Ma; Alexander Pertsemlidis
Journal:  Cancer Lett       Date:  2018-04-13       Impact factor: 8.679

2.  miR-30a-5p enhances paclitaxel sensitivity in non-small cell lung cancer through targeting BCL-2 expression.

Authors:  Xiaojie Xu; Shuai Jin; Yongfu Ma; Zhongyi Fan; Zhifeng Yan; Wenchao Li; Qi Song; Wenye You; Zhaohui Lyu; Yeqiong Song; Pingan Shi; Ying Liu; Xiao Han; Ling Li; Ying Li; Yang Liu; Qinong Ye
Journal:  J Mol Med (Berl)       Date:  2017-05-09       Impact factor: 4.599

Review 3.  Recent progress with microtubule stabilizers: new compounds, binding modes and cellular activities.

Authors:  Cristina C Rohena; Susan L Mooberry
Journal:  Nat Prod Rep       Date:  2014-03       Impact factor: 13.423

4.  Delivery of baicalein and paclitaxel using self-assembled nanoparticles: synergistic antitumor effect in vitro and in vivo.

Authors:  Wei Wang; Mei Xi; Xuezhong Duan; Yong Wang; Fansheng Kong
Journal:  Int J Nanomedicine       Date:  2015-05-22

5.  The miR-200 family differentially regulates sensitivity to paclitaxel and carboplatin in human ovarian carcinoma OVCAR-3 and MES-OV cells.

Authors:  Anamaria Brozovic; George E Duran; Yan C Wang; E Brian Francisco; Branimir I Sikic
Journal:  Mol Oncol       Date:  2015-05-16       Impact factor: 6.603

6.  MiR-125a promotes paclitaxel sensitivity in cervical cancer through altering STAT3 expression.

Authors:  Z Fan; H Cui; H Yu; Q Ji; L Kang; B Han; J Wang; Q Dong; Y Li; Z Yan; X Yan; X Zhang; Z Lin; Y Hu; S Jiao
Journal:  Oncogenesis       Date:  2016-02-15       Impact factor: 7.485

7.  MiR-409-5p as a Regulator of Neurite Growth Is Down Regulated in APP/PS1 Murine Model of Alzheimer's Disease.

Authors:  Jing Guo; Yifei Cai; Xiaoyang Ye; Nana Ma; Yuan Wang; Bo Yu; Jun Wan
Journal:  Front Neurosci       Date:  2019-11-28       Impact factor: 4.677

Review 8.  Antimitotic drugs in the treatment of cancer.

Authors:  Rustelle Janse van Vuuren; Michelle H Visagie; Anne E Theron; Annie M Joubert
Journal:  Cancer Chemother Pharmacol       Date:  2015-11-12       Impact factor: 3.333

9.  miR-21 Expression in Cancer Cells may Not Predict Resistance to Adjuvant Trastuzumab in Primary Breast Cancer.

Authors:  Boye Schnack Nielsen; Eva Balslev; Tim Svenstrup Poulsen; Dorte Nielsen; Trine Møller; Christiane Ehlers Mortensen; Kim Holmstrøm; Estrid Høgdall
Journal:  Front Oncol       Date:  2014-08-15       Impact factor: 6.244

10.  MiR-770-5p inhibits cisplatin chemoresistance in human ovarian cancer by targeting ERCC2.

Authors:  Henan Zhao; Xiaotang Yu; Yanfang Ding; Jinyao Zhao; Guang Wang; Xian Wu; Jiyong Jiang; Chun Peng; Gordon Zhuo Guo; Shiying Cui
Journal:  Oncotarget       Date:  2016-08-16
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.